Stifel raised the firm’s price target on Abbott (ABT) to $145 from $135 and keeps a Buy rating on the shares. Abbott’s resilient Q1 performance, reiterated 2025 guidance, and bullish commentary related to potentially increasing guidance if not for tariff headwinds, all firmly place Abbott within the “quality growth” idea category in a moment of large-scale macroeconomic uncertainty, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories: Strong Growth and Resilience Justify Buy Rating
- Abbott price target raised to $147 from $136 at Wells Fargo
- Abbott price target raised to $159 from $158 at Barclays
- Abbott Laboratories Reports Strong Q1 2025 Results
- Abbott Laboratories: Strong Buy Rating Amid Robust Financial Performance and Growth Potential